Genome & Company Corrects Stock Option Grant – Exercise Price Sharply Reduced, Shares Increased

Correction to initial filing (Mar 28, 2024): Grantees 51→45, shares granted 445,030→804,460
Exercise price lowered from 9,940 won to 3,040 won (contractual adjustment due to capital increases)
Total outstanding options increased from 1,941,396 to 4,092,568 shares
Fair value per option increased from 3,483 won to 5,893 won (Black-Scholes model)
Key assumptions: closing price before grant 9,130 won, expected volatility 56.84%, risk-free rate 3.15~3.67%